And other biotech news brought to you by The Readout.

And more pharma news updates from Pharmalittle.

Matcha, a vibrant green tea powder with ancient Japanese roots, has exploded in popularity worldwide. From traditional tea ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. | ITV National News ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

Benjamin Izar is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, GSK, Eisai, AstraZeneca and Merck, and has received research funding to ...

The National Health Service will not fund two new Alzheimer’s drugs after an official review concluded the treatments cost ...